Dermapharm Holding SE

DMP

DE000A2GS5D8

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 05:32:27 2024-05-16 am EDT			5-day change	1st Jan Change
37.42 ^EUR	+3.24%		+7.42%	-11.08%

May. 15	Drug manufacturer Dermapharm starts the new year with declines	DP
May. 15	WDH/Pharmaceuticals manufacturer Dermapharm starts the new year with declines	DP

Dermapharm Holding SE Provides Revenue Guidance for the Fiscal 2020

August 21, 2020 at 01:30 am EDT

Dermapharm Holding SE provided revenue guidance for the fiscal 2020. For the period, the company raised revenue to be in the range of 12% to 15%.

Latest news about Dermapharm Holding SE

Drug manufacturer Dermapharm starts the new year with declines	May. 15	DP
WDH/Pharmaceuticals manufacturer Dermapharm starts the new year with declines	May. 15	DP
DERMAPHARM : Berenberg keeps its Buy rating	Apr. 04	ZD
Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Dpa-AFX Overview: COMPANIES from 14.03.2024 - 15:15	Mar. 14	DP
Dermapharm looks cautiously into the future - missing Covid business	Mar. 14	DP
DERMAPHARM : Berenberg reaffirms its Buy rating	Dec. 07	ZD
DERMAPHARM : Berenberg reiterates its Buy rating	Nov. 16	ZD
Dpa-AFX Overview: COMPANIES from 15.11.2023 - 15:15	Nov. 15	DP
Dermapharm grows thanks to new subsidiary - nutritional supplements in demand	Nov. 15	DP
DERMAPHARM : Jefferies reiterates its Buy rating	Nov. 15	ZD
Dermapharm Holding SE Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
Dermapharm grows thanks to subsidiary Arkopharma and dietary supplements	Nov. 15	DP
DERMAPHARM : Buy rating from Berenberg	23-10-19	ZD
DERMAPHARM : Berenberg maintains a Buy rating	23-09-21	ZD
Dermapharm Holding SE Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
DERMAPHARM : Jefferies keeps its Buy rating	23-08-29	ZD
Dermapharm move to SDax top - Jefferies praises profitability	23-08-16	DP
Dermapharm becomes more optimistic after first half-year - share price jumps	23-08-16	DP
Jefferies leaves Dermapharm at 'Buy' - Target 65 euros	23-08-16	DP
DERMAPHARM : Jefferies reiterates its Buy rating	23-08-16	ZD
Dermapharm becomes more optimistic after first half year	23-08-16	DP
Dermapharm Holding SE Provides Earnings Guidance for the Year 2023	23-08-16	CI
DERMAPHARM : Jefferies gives a Buy rating	23-08-14	ZD
DERMAPHARM : Berenberg keeps its Buy rating	23-06-20	ZD

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.

Sector

Pharmaceuticals

Calendar

2024-06-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Dermapharm Holding SE

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

36.25 EUR

Average target price

56.9 EUR

Spread / Average Target

+56.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DERMAPHARM HOLDING SE	-11.08%	2.12B
ELI LILLY AND COMPANY	+35.01%	709B
NOVO NORDISK A/S	+30.61%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.17%	239B
NOVARTIS AG	+9.38%	211B
ROCHE HOLDING AG	-3.27%	203B
AMGEN INC.	+10.77%	171B

Other Pharmaceuticals